Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Medical Oncology
•
Primary Care
How often do you offer repeat imaging for patients with life expectancy>10 years and BCR prostate cancer with PSADT>10 months while they are on observation?
Related Questions
Would you recommend patients with newly diagnosed bladder cancer to discontinue SGLT2 inhibitors?
How do you approach patients who are inappropriately worried/fixated on a test result that is flagged as abnormal but not clinically significant?
Would you use T-DXd as a first-line agent for a patient who developed early metastatic relapse of HER2+ urothelial cancer shortly after standard perioperative chemo/immunotherapy, over other standard non-targeted treatments?
How do you decide between radioligand therapy or cytotoxic chemotherapy in patients with metastatic castration-resistant prostate cancer with prior ARPI exposure who have cancer-related anemia?
Should a patient who requires definitive treatment for prostate cancer as a pre-transplant requirement be strictly required to complete their course prior to transplant/initiation of immunosuppression?
How, if at all, are you modifying your practice and clinical workflow for patients receiving checkpoint inhibitors with data showing improved outcomes for patients receiving infusions earlier in the day?
How do you assess and counsel women with chronic post-lumpectomy or mastectomy pain?
How do you manage PSA progression while a patient is on Xofigo or Pluvicto?
How do you counsel patients/families whose goals of care are clearly aligned with a comfort-focused, end-of-life approach, but who are hesitant to formally enroll in hospice?
In which patients are referring for focal gland therapy for localized prostate cancer?
